SOUTH SAN FRANCISCO, Calif. (AP) — SOUTH SAN FRANCISCO, Calif. (AP) — CytomX Therapeutics Inc. (CTMX) on Thursday reported third-quarter profit of $5.8 million.
On a per-share basis, the South San Francisco, California-based company said it had profit of 7 cents.
The results surpassed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 16 cents per share.
The biopharmaceutical company posted revenue of $33.4 million in the period, also topping Street forecasts. Five analysts surveyed by Zacks expected $18.9 million.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CTMX at https://www.zacks.com/ap/CTMX
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.